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ABSTRACT
Shiga toxin-producing Escherichia coli (STEC) are usually found on food products due to contam-
ination from the fecal origin, as their main environmental reservoir is considered to be the gut
of ruminants. While this pathogen is far from the incidence of other well-known foodborne bac-
teria, the severity of STEC infections in humans has triggered global concerns as far as its inci-
dence and control are concerned. Major control strategies for foodborne pathogens in food-
related settings usually involve traditional sterilization/disinfection techniques. However, there is
an increasing need for the development of further strategies to enhance the antimicrobial out-
come, either on food-contact surfaces or directly in food matrices. Phages are considered to be a
good alternative to control foodborne pathogens, with some phage-based products already
cleared by the Food and Drug Administration (FDA) to be used in the food industry. In European
countries, phage-based food decontaminants have already been used. Nevertheless, its broad
use in the European Union is not yet possible due to the lack of specific guidelines for the
approval of these products. Furthermore, some safety concerns remain to be addressed so that
the regulatory requirements can be met. In this review, we present an overview of the main viru-
lence factors of STEC and introduce phages as promising biocontrol agents for STEC control. We
further present the regulatory constraints on the approval of phages for food applications and
discuss safety concerns that are still impairing their use.
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Shiga toxin-producing Escherichia coli (STEC)
Escherichia coli colonizes every mammal on the planet
[1], and was first described in 1885 by the German
physician Theodor Escherich [2]. Since then, E. coli has
become one of the most well studied bacterial species
[3]. Escherichia coli is a Gram-negative, non-sporulating
facultative anaerobe that inhabits the intestines, being
the most represented aerobe in the gastro-intestinal
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(GI) tract, outnumbered by anaerobic bacteria by 100/1
to 10,000/1 [2,4]. Most E. coli strains belong to a hetero-
geneous group, typically nonpathogenic and beneficial,
in the normal intestinal microbiome. However, there
are some E. coli strains that are considered pathogenic
to humans, such as the diarrheagenic group associated
with GI diseases [5–7]. The most important diarrhea-
genic E. coli pathogens are divided into 6 classes:
enteropathogenic (EPEC), enteroinvasive (EIEC), entero-
toxigenic (ETEC), enteroaggregative (EAEC), diffusely
adherent (DAEC), and Shiga toxin-producing (STEC)
(where enterohemorrhagic (EHEC) is a major subset)
[5,6]. Recently, a new class of adherent invasive (AIEC),
has also been described [8]. This division reflects the
complexity and diversity of strains within this species,
with some of them being allocated to different groups
depending on the virulence gene being screened [8,9].
Among the pathogenic classes, STEC strains are the
ones that are most commonly associated with severe
foodborne outbreaks [10].
STEC strains are characterized by the presence of the
Shiga toxin 1 and/or 2 genes (stx1 and stx2), typically
acquired through a lambdoid bacteriophage [8], and
are responsible for a number of human diseases, such
as mild to severe diarrhea. The subset EHEC is normally
associated with more severe conditions such as hemor-
rhagic colitis (HC) and hemolytic uremic syndrome
(HUS). The latter frequently leads to renal failure among
young children, as well as renal complications [11–13].
EHEC possesses the genes responsible for causing
attaching-effacing (A/E) lesions on intestinal epithelial
cells (such as EPEC), encoded on the Locus of
Enterocyte Effacement (LEE) pathogenicity island, and
express high levels of Stx toxins [11]. Although several
OH serotypes have been identified, the STEC O157:H7
serotype is the most well-known among them, in add-
ition to being the most studied one. The US
Department of Agriculture (USDA) has considered this
serogroup as being a food adulterant since 1994. The
“Big 6” non-O157 STEC strains, O26, O45, O103, O111,
O121, and O145, are usually found associated with
severe disease in humans, and were also declared as
adulterants [8]. In 2016, in “trends and sources of zoo-
noses, zoonotic agents and food-borne outbreaks,” the
European Food Safety Agency (EFSA) reported that in
Europe the most prevalent serogroups following O157
were O26, O103, O91, O145, O146, and O128 [14].
There are several schemes for STEC classification, and
the simplest is the one that divides into E. coli O157
and non-O157 STEC. This scheme is based on the preva-
lence of the O157 serotype [15], but over the last years,
other serotypes are increasing their prevalence.
The transmission of STEC occurs via the fecal-oral
route, usually occurring by the intake of contaminated
food or water, direct contact with animals, or person-
to-person transmission. The major reservoirs are rumi-
nants, especially cattle [15]. The known infectious dose
for STEC is very low (less than 100 microorganisms)
[13], and these strains are able to form viable-but-non-
culturable cells capable of producing Shiga toxin [8],
which can make the detection and control of these
pathogens even more difficult.
Virulence factors of STEC
As previously discussed, the presence of the genes
encoding for Shiga-toxin (Stx) 1 and 2 is considered as
the major virulence factor of STEC strains, and the latter
is associated with more severe disease outcomes.
Besides the type of a specific Stx and its potency, the
amount of Stx toxin produced is another important fac-
tor to take into account when evaluating the virulence
outcome [16]. Each type of Stx has variants: Stx1 has 3
(a, c and d), and Stx2 has 7 variants (from a to g) [8].
STEC strains can either carry one gene for Stx1 or Stx2,
both genes, or a combination of Stx2 variants. Strains
containing the variants of Stx2a and Stx2c are most
commonly isolated from HUS cases [8,16–18]. The Shiga
toxin is an AB5, in other words, it is composed of a cata-
lytic A subunit, and a pentamer of B subunits, respon-
sible for the recognition and binding to receptors.
Initially, in 1986, it was demonstrated by Jacewicz et al.
that the Shiga toxin could bind to the glycosphingoli-
pid globotriaosylceramide (Gb3) [19]. Nowadays, how-
ever, it is well known that toxin subtypes can bind to
other receptors with different affinities. Stx1a prefers
Gb3, but can also bind to globotetraosylceramide
(Gb4), in turn, Stx2a binds preferentially to Gb3. Stx2e is
the subtype with a wider range of receptors, preferring
Gb4, but also binding to Gb3, pentahexosylceramides
with Gb4-elongated core structures, and globopentao-
sylceramide (Gb5) [20]. After binding to the receptor,
the Shiga toxin is internalized by the cell, and trans-
ported to the Golgi apparatus. Then, the A subunit that
consists of 2 fragments connected by an internal disul-
fide bond, is cleaved by the enzyme furin, and the A1
fragment is transported into the cytoplasm. A1, has an
RNA N-glycosidase activity and inactivates the 60S sub-
unit, inhibiting protein synthesis [20,21].
The Shiga toxin gene is acquired by E. coli strains
through the insertion of a prophage, known as Shiga
phage. Shiga phages are lambdoid phages capable of
inserting themselves in specific sites into the chromo-
some of several E. coli serogroups [16,17,22,23], and
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even other members of the Enterobacteriaceae family,
such as Salmonella enteriditis serovars Cholerasuis,
Typhi, and Typhimurium [24]. Stx phages, as lambdoid
phages, prefer the lysogenic state, that is, they are sta-
ble until some stress factor triggers an S.O.S. response
of the cell. Some examples of stress factors include
DNA damaging agents, such as several antibiotics like
mitomycin C, olaquindox [25,26], or ciprofloxacin [27],
in addition to some external factors, such as UV irradi-
ation and High Hydrostatic Pressure [17]. The S.O.S.
response leads to the lytic cycle, resulting in phage rep-
lication and subsequent bacterial lysis. During this pro-
cess, the Stx toxin is expressed and released [28].
Iversen et al. [29] studied some commensal E. coli that
was lysogenized by a prophage from the highly virulent
EHEC strain, O103:H25 (NIPH-11060424), which was
responsible for the 2006 Norwegian outbreak. Most of
the newly lysogenized E. coli produced more phages
than the original strains, and a few even produced the
phage without any induction agent. This result suggests
that the stx gene can be easily transferred through
transduction to commensal E. coli, which in turn will
spread the toxin gene further, as it might have been
the case during the 2006 outbreak [29].
Each Stx phage has only one stx gene, however,
since there are several Stx phages in the environment
with high genetic diversity, especially in the integrase
gene, more than one Stx phage can integrate into the
same bacterial chromosome at different insertion sites
[16]. In the study of Steyert et al. [16], it is shown that
what determines the insertion site is the phage inte-
grase rather than the availability of the insertion sites.
Furthermore, it is proven that integrases and stx genes
have no phylogenetic correlation [16]. Stx phages are
players on the horizontal gene transfer that drives the
evolution of STEC strains. An example of this is the
emergence of a new serogroup that encodes stx genes,
the hybrid EAEC/STEC E. coli O104:H4 which has
recently acquired the stx2 gene [8,30]. Furthermore,
some STEC strains have the ability to frequently lose
and acquire Stx phages, such as STEC O26:H11, both
in vitro and in vivo [25,31]. This also increases the diver-
sity of prophages being exchanged among related E.
coli in the environment.
The subset EHEC, or LEE-Positive STEC, is frequently
characterized by the presence of the LEE pathogenicity
island, which is a 35 kb chromosomal pathogenicity
island [15,16,32]. A/E lesions occur by the attachment
of the bacteria to the host cell, mediated through the
destruction of the microvilli, and beneath the attach-
ment site, there is a production of actin filaments,
called actin pedestals, and other cytoskeletal proteins.
In the LEE pathogenicity island, an adhesion intimin is
encoded, which is an outer membrane adhesin protein
encoded by the eae gene, its translocated receptor Tir,
a type III secretion system (T3SS), and several effectors
[15,32]. However, not all STEC strains that cause HC and
HUS are Lee- and eae-positive [13]. Some LEE-negative
STEC have been known to cause severe diarrheal symp-
toms and HUS. While the Stx toxin is an important fac-
tor of virulence, it is not the sole factor responsible for
the progression of HUS. This means that most LEE-
negative STEC strains have an LEE-independent mech-
anism of adherence responsible for their virulence.
Steyert et al. [16] studied 9 LEE-negative isolates (7V,
94C, B2F1, C165-02, DG131, EH250, MHI813, 031, S1191)
and demonstrated that they do not present a common
virulence factor for adhesion.
Several other virulence factors have already been
identified, such as the long polar fimbrial gene cluster,
and others in virulence plasmids, such as the pO113.
This plasmid, as well as pO157, carries genes encoding
enterohemolysin (ehxA) and serine protease autotrans-
porter of Enterobacteriaceae (espP). Other virulence
genes were exclusively found in LEE-negative strains,
like the STEC autoagglutinating adhesion (saa) [16].
Information on virulence determinants has been arising
very quickly, and there are already a large number of
genes to take into account when evaluating the patho-
genic potential of E. coli. Table 1 presents an overview
of the virulence factors so far described, as well as their
potential role in the infection mechanisms [8,32].
Europe and STEC – what has been conducted
so far
Programs for the surveillance and prevention of O157
and non-157 STEC are being implemented in Europe,
the USA, and in other countries, and are considered of
extreme importance for the efficiency on STEC control.
In the European Union, all member countries are obli-
gated to report any outbreak and annual reports are
also published. In these reports, a thorough analysis of
the epidemiological characteristics of infections
is provided.
In 2015, 30 European Union/European Economic
Area (EU/EEA) member countries reported STEC infec-
tions, accounting for 6151 confirmed cases. The rate
was 1.5 cases per 100,000 population, keeping within
the same values as those in the preceding three years.
In 2011, there was a large outbreak due to EAEC/STEC
O104:H4 contamination on raw sprouted fenugreek
seeds, which infected more than 3800 people located
in Germany alone, in addition to more cases in 15 other
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Table 1. Some of the virulence factors described for STEC, and their role in pathogenesis.
Virulence factor Gene/operon Role in pathogenesis Ref.
Shiga toxin stx1 (a, c, and d) and
stx2 (a to g)
Stx toxin is composed by 2 subunits, A and B. The A
subunit is a RNA-glycosidase that interacts with the
60S rRNA, inhibiting protein synthesis, causing
cell death.
[8]
Locus of Enterocyte Effacement
(LEE) pathogenicity island (PAI)
LEE-PAI encodes several genes involved in the adhesion
mechanism called attaching-and-effacing (A/E) lesion,
such as type III secretion system (TTSS), an outer
membrane adhesion (intimin), its translocated intimin
receptor (TIR), and secreted proteins with signal
transduction.
[32]
Intimin eae The eae gene is carried by the LEE-PAI, encoding an
outer membrane adhesion protein, called Intimin.
This protein interaction with the bacterial
translocated intimin receptor (Tir) leads to the
attachment of STEC cell to the host intestinal
mucosa, resulting on the A/E lesions.
[8,33]
Cytolethal distending (CDT-V) toxin cdtA, cdtB, cdtC CDT is a tripartite toxin composed of three peptides
(CdtA, CdtB and CdtC). It is believed that CdtB is the
catalytic domain with DNase I-like activity, that when
in the nucleus of the host cell triggers the DNA
damage response, impairing the cell cycle. CdtA and
CdtC are responsible for cell recognition and CdtB
transportation into the nucleus.
[34]
EHEC hemolysin (EHEC-Hly) ehxA or EHEC-hlyA EHEC-hlyA is part of an operon composed by four genes
(EHEC-hlyC, EHEC-hlyA, EHEC-hlyB, EHEC-hlyD),
encoded on the pO157 plasmid. EHEC-hlyA codes the
structural protein of EHEC-Hly. The proteins coded by
EHEC-hlyB and EHEC-hlyD are responsible for the
transport of EHEC-Hly out of the bacterial cell, in its
turn EHEC-hlyC product is responsible for EHEC-Hly
pos-translational activation. EHEC-Hly is responsible
for forming pores into the cell membrane, and is
found as free, or in association with outer membrane
vesicles (OMV). Both forms target the human
intestinal epithelial and microvascular endothelial
cells, but in different manners. When in the free
form EHEC-Hly is responsible for lysing the cells, but





ehaA, ehaB, and ehaJ Encoded in the LEE-PAI, belongs to the adhesin
involved in diffuse adherence family, and is involved
in attachment to biological and abiotic surfaces.
[8,33]
Serine Protease Autotransporters espP Encoded on the pO157 plasmid, it is important for




Biofilm formation or Sab
sab Involved in the adherence to abiotic surfaces and
epithelial cells. It is thought to be involved in the
adherence to enterocytes of STEC strains that lack





cah Encoded in the LEE-PAI, this autotransporter is involved
in bacterial autoaggregation, promoting bacterium-
to-bacterium interactions.
[8,33]
Adhesins eibG, efa-1/lifA/toxB Immunoglobulin-binding (Eib) G is encoded by the
gene eibG, and can bind to human IgD and IgA. It
can also participate in bacterial adhesion to host
epithelial cells. Toxin Efa-1 is similar to LifA and
ToxB, and they are thought to be associated with
cell adherence, lymphostatin activity, or induction of
secretion of type III effectors in the STEC strain.
[33]
Long Polar Fimbriae and E. coli
YcbQ laminin-binding
fimbriae (ELF).
lfp and elf Able to attach the extracellular matrix protein laminin,
which contributes to colonization of the GI tract.
[8,33]
Hemorrhagic coli pilus (HCP) type
IV pilus
hcpA Forms long bundled fibers, which recognize matrix
proteins on epithelial cells. Involved in biofilm
formation, twitching motility, and in vitro
cell invasion.
[8]
Subtilase cytotoxin subAB Believed to be more toxic than Stx toxin, SubAB is
internalized and trafficked to the endoplasmic
reticulum (ER). The interaction of SubAB with a
regulator of stress response in the ER, leads to cell
death. Though to be involved with
immune responses.
[8]
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countries. This implied an increment of about 1.8-fold,
compared to the situation reported in 2010. However,
the rate of prevalence stabilized between 2012 and
2015. In 2015, four outbreaks were reported, according
to the European Center for Disease Prevention and
Control (ECDC) “due to food contamination, being the
sources ‘mixed leaf lettuce and raw minced lamb,’
‘chicken burgers and beef burgers’, and ‘various meat
products’” [36].
In 2016, STEC was the fourth most reported zoonosis
with 6378 confirmed cases, and the rate was 1.82 cases
per 100,000 population, which represents an 8.3%
increase when compared with the values from 2015.
The higher published rate may have arisen due to the
stricter surveillance carried out after the outbreak, with
the use of PCR for the detection of STEC in stool sam-
ples. The serogroup most commonly reported was
O157 with 38.6% of the cases, which represented a
decrease in relative proportion in relation to non-O157
serogroups. The second most reported serotype was
O26, representing the most frequent cause of HUS.
Increased detection of non-O157 strains is related to
the rising awareness of the danger of these strains,
which led to an increase in the number of laboratories
testing food products to O157 and, more recently, other
serogroups [14]. STEC and other classes of E. coli-associ-
ated infections are usually linked either to fecal contam-
ination of carcasses and/or to surfaces during the food
processing steps or, as is the case with fresh vegetables
and fruits, due to irrigation with contaminated water.
Surveillance reports also indicate the alarming preva-
lence of antibiotic-resistant STEC. In fact, a few reports
have shown that a number of STEC strains isolated
from food, animals, and humans, are resistant to some
antimicrobials, such as lactams, carbapenem, and tetra-
cycline [37,38]. Antibiotic-resistant bacteria that result
from the misuse of antibiotics on farm animals can
reach the population if present on food products of ani-
mal origin and is also due to other cross-contamination
events [39]. Good manufacturing practices (GMPs) and
Hazard Analysis Critical Control Point (HACCPs) have
been implemented in food industries as a way to guar-
antee food safety. Despite their implementation and
the fewer cases of foodborne contamination, foodborne
outbreaks continue to occur [40]. The combination of
these facts contributes to identifying the urgency of
finding new strategies to control foodborne bacteria,
thus keeping the environment and human health
safety, in addition to reducing the harmful effects
caused by the misuse of antibiotics.
The European Union allows the use of substances
other than potable water for the decontamination of
foodstuff of animal origin and food-contact surfaces,
providing that the substances undergo a safety and
efficiency evaluation before their authorization clear-
ance by the competent entities (Regulation (EU) 853/
2004). At the moment, only one substance has obtained
this authorization – Latic Acid to be used on bovine
meat (Retrieved from EFSA https://www.efsa.europa.eu/
en/applications/biologicalhazard/faq in May 2020). Not
only chemical substances can be used, but biological
agents can be considered as well. Bacteriophages are
among the biological agents that have already been
submitted for analysis.
Bacteriophages – why?
Bacteriophages (phages) are obligate bacterial viruses.
The first evidence of the existence of phages occurred
in 1896 and 1898, when strong antibacterial activity
was observed in Vibrio cholera and Bacillus subtilis,
respectively [41]. However, it was Frederick Twort, an
English medical bacteriologist, when observing a similar
phenomenon in Micrococcus in 1915, suggested that
viruses were responsible for this activity [41–43]. In
1917, the French-Canadian microbiologist d’Herelle,
observed an “invisible microbe” present in bacteria-free
filtrates of stool samples from dysentery patients [44].
These “invisible microbes” were responsible for the lysis
of liquid suspensions, and for the creation of clear
zones in bacterial lawns. d’Herelle, explained, for the
first time, that these viruses replicate at the expense of
bacteria, leading to their death and subsequent lysis
[41]. Phages outnumber bacteria tenfold, and it is esti-
mated that the phage population is composed of about
1031 phage particles, they being the most abundant
entities on Earth [41,45]. Considered as a very heteroge-
neous group, phages are classified not only by their
nucleic acid composition (dsDNA, ssDNA, dsRNA, and
ssRNA) but also by their morphologic structure. Most
phages are tailed (about 96%) and belong to the order
Caudovirales. Until recently, Caudovirales’ phages were
further classified into one of three families, Podoviridae
(short tail), Siphoviridae (long non-contractile tail), and
Myoviridae (contractile tail) [46]. Nevertheless, due to
the high genetic diversity, some phages of the family
Myoviridae have been reclassified into one of two new
families - Ackermannviridae and Herelleviridae [47].
Phages can be found wherever is their specific host
since they need a viable bacteria cell to replicate and
propagate [48]. The phage replication cycle starts with:
adsorption, penetration, replication of nucleic acids,
and the formation of virions. This will lead to lysis and
subsequent release from the cell. Phages are usually
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specific for bacterial species, or even strain-specific.
Notwithstanding this, there are some phages that are
able to infect different species. The specificity is deter-
mined by the presence of receptors located on the sur-
face of bacterial cells, such as LPS fragments or other
surface proteins [49]. There are two types of phages,
temperate or lytic, depending on the life cycle they
enter upon infection. The infection of lytic phages
always leads to the lysis of the host with the release of
the progeny. As such, lytic phages are the chosen ones
for antimicrobial applications. On the other hand, tem-
perate phages enter the lysogenic cycle, which means
that their genome will integrate and coexist on the
host genome in a stable manner (known as prophage),
replicating whenever the host cell also replicates.
Temperate phages can enter the lytic cycle if an exter-
nal factor (usually causing some stress into the cell),
leads to the prophage induction (Figure 1). The switch
from lysogenic to the lytic state has been a relevant
matter of study in the past few years [28,50–52]. Some
phages, like the lambdoid Stx phages, depend on the
activation of the RecA-dependent bacterial S.O.S. that is
usually damaged on the single-stranded DNA frag-
ments. Prophage induction occurs after the RecA pro-
tein, an important recombinase from the DNA repair
system, stimulates the cleavage of an S.O.S. regulon
repressor (LexA protein) and a cI phage repressor, lead-
ing to the production of phage progeny (See explan-
ation in Figure 1(A)) [53,54]. Stx phages take advantage
of the S.O.S. response when infecting mammalian cells.
For example, if in contact with H2O2 or superoxide
released by the leukocytes and neutrophils, the S.O.S.
response is activated, and thus the Stx toxin is pro-
duced and released, leading to the death of eukaryotic
cells. Nevertheless, some studies demonstrate that
spontaneous induction is an important feature of Stx
phages which requires a smaller amount of RecA for
the induction to occur [55].
In the context of food safety, lytic phages are inter-
esting tools [48]. Phages are considered a natural agent,
Figure 1. The life cycles of a bacteriophage. The first step on phage replication cycles is attachment to the host cell by the rec-
ognition of receptors into the bacterial membrane (Adsorption). Then, phages inject their genome into the cell and enter the lytic
cycle or the lysogenic cycle. Phages that enter the lytic cycle have their genome transcribed and translated into new phage par-
ticles that are then released from the cell by lysis. In the lysogenic cycle, the phage’s genome inserts itself into the bacterial
chromosome coexisting as a prophage, in a stable manner until some external (stress for the bacteria) factor causing prophage
induction, leading to the lytic cycle. (A) RecA protein binds to single-strand DNA, resulting in the cleavage of LexA and cI phage
repressor. LexA cleavage leads to the expression of S.O.S. genes. Furthermore, the expression of S.O.S genes can lead to the pro-
duction of repressor proteins that will bind to the prophage repressor, resulting in its excision, and starting the lytic cycle.
1086 G. PINTO ET AL.
in contrast to other food chemical preservatives that
are associated with severe health problems, such as
cancer, asthma, and others [56]. Recently, there has
been an increase in the popularity of green and non-
chemical technology concerning the control of food
contamination [48,57]. When compared to other bio-
cides (including antibiotics), phages present several
advantages. They are highly specific toward one spe-
cies; so far there are no known side effects toward
mammalian cells. They are present in all environments,
including food products; and are known to be active
against biofilm structures and they do not alter food
organoleptic properties [48,57]. In the last few years,
considerable research on the use of phages to control
E. coli contamination in the context of food safety has
been accomplished. Phages can be applied in the food
chain, from pre-slaughtering (reviewed elsewhere [48])
to food products and food industry processing.
Bacteriophages for controlling E. coli populations
Numerous studies accomplished hitherto have already
demonstrated the capability that phages possess to
control enteric E. coli on food products. An overview of
the studies performed over the last few years (from
2011 to present times) is provided in (Supplementary
information Table 1). A good example of phage applica-
tions in food is offered by Tomat et al. [58,59]. In their
study, they characterized 2 phages, DT1 and DT6, which
have been isolated from the stool samples of patients
with diarrhea. When tested on meat products, a signifi-
cant reduction of viable cells of EPEC and STEC (around
1 log for single phage application and 2 log for cocktail)
were observed, when compared to the controls without
phages, at both temperatures tested (5 and 24 C). The
best phage efficacy was obtained when phages were
applied at concentrations ranging from 1.4 109 to
1.7 1010 PFU/mL, which corresponds to a Multiplicity
of Infection (MOI) of 2.2 102 (for single phage applica-
tions) to 3.33 105 (cocktail application) and were
shorter observed after phage application (3- and 6-h).
The aforesaid authors also demonstrated that the
phage did not lyse nonpathogenic strains, targeting
only the pathogenic ones. A low emergence of
Bacteriophage Insensitive Mutants (BIMs) was recorded.
Furthermore, mutants isolated after inoculation with
phage DT6, showed reversion unlike mutants resistant
to phage DT1 which maintained their resistance after
several rounds of subculture [58]. The same phages,
DT1 and DT6, were used as biocontrol tools for STEC,
EPEC, and as a nonpathogenic E. coli strain on milk fer-
mentation. Both phages, either individually or in a
cocktail, were able to control the growth of all E. coli
strains without compromising the starter culture – the
species Streptococcus thermophiles 10-C [59].
Similar, to what happens in meat or milk, in seafood
the contamination by enteric bacteria due to inappro-
priate food-handling practices can also lead to food-
borne diseases and to significant revenue losses. Le
et al. [60] used phages to control both E. coli and
Salmonella enterica subsp. enterica strains, as single and
combined applications. The treatment resulted in a
reduction of these bacteria in oysters [60].
Reports on the efficiency of a cocktail of three lytic
phages specific for E. coli O157:H7 (under the trademark
EcoShieldTM by the North American company Intralytix,
Inc.) in lettuce are good examples of the antimicrobial
effects of phages in freshly cut vegetables [61–65]. The
phage cocktail solution has been applied in two differ-
ent ways: by immersion or spraying the lettuce. Both
forms of application led to a reduction of viable cells.
The 2min immersion in higher titer phage solutions
resulted in the reduction of E. coli cells to undetectable
levels at days 6 and 7. The spraying technique was very
effective at immediately reducing E. coli O157:H7 popu-
lations on freshly cut lettuce; it is believed that the
spraying technique disperses more phages on the let-
tuce surface. Furthermore, phage treatment can be
used synergistically with a hypochlorite solution [61].
Apart from the food samples, some phages have
also been tested in environmental samples associated
with the food processing settings. In this regard, bio-
films play an important role in the food industry. This
ability of bacteria to attach to the surface of both food
products, or to the facilities that constitute a reservoir
for food contamination, which endangers human health
[40]. Biofilms are a community of bacteria cells pro-
tected in an extracellular matrix [40] which can be com-
posed of: polysaccharides, proteins, nucleic acids, and/
or lipids, with channels that allow for the distribution of
key resources. The biofilm structure protects bacteria
not only from external environmental damages but also
from antimicrobial agents and the host immune system.
Dalmasso et al. [66] isolated three new phages and
characterized them in terms of their anti-biofilm poten-
tial. All three phages have been tested against biofilms
for periods of 24 and 48 h individually and in a cocktail.
The cocktail composed of the three phages, was the
better option found for biofilm control since it pre-
vented the formation of BIMs. In another study, Cui
et al. [67] performed sequential treatment with Cold
Nitrogen Plasma (CNP) and phages in order to control
the formation of E. coli O157:H7 biofilms. This sequen-
tial treatment provided a reduction of 5.71 log CFU/
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cm2, quite higher than the ones observed for CNP or
the phages alone (about 2 log CFU/cm2) [67]. In 2017,
Sadekuzzaman et al. [68] reported the treatment of bio-
films formed by strains ATCC 43889, NCCP 11090, and
NCCP 14541 on different surfaces (stainless steel, rub-
ber, and leaf) at two different temperatures (10 and
30 C), using the lytic phage BPECO 19. After 2-h, phage
BPECO 19 was able to reduce bacteria numbers of bio-
films formed at both temperatures and on different sur-
faces, with lower efficacy on the leaf surface. Overall,
the results suggest that the phage can control biofilms
at different temperatures. However, the type of surface
influences the biocontrol outcome [68]. The applicabil-
ity of phages to control biofilms formed on surfaces of
stainless steel used during vegetable harvesting was
demonstrated by Patel et al. [69]. In this study, spinach
harvester blades were inoculated with a spinach extract
containing five E. coli O157:H7 strains for 48-h. A phage
cocktail (8 log PFU/mL) was used to spray each side of
the blade. After 2-h, at room temperature (22 C), the
population of E. coli cells (initially of 4.87 CFU/blade)
was reduced to undetectable levels [69]. The study of
Lee et al. [70] showed that a cocktail composed by
phages BECP2 and BCEP6 was efficient at reducing E.
coli O157:H7 biofilms formed on glass wool, microtiter
plates, and stainless steel coupons [70]. Tomat et al.
[71], on the other hand, chose glass coverslips and
stainless steel as food processing materials as represen-
tatives to form biofilms. A cocktail composed by phages
DT1 and DT6 was used to treat EPEC920 and O157:H7
STEC464 biofilms, and another cocktail composed by
DT5 and DT6 to treat non-O157 STEC ARG4827. As a
control, the hard surfaces were treated with Hershey-
Mg broth, or not treated at all (dry control). Treatments
were performed at 4 and 37 C, for 1, 3, and 24-h peri-
ods. Biofilms formed on both materials were reduced at
both temperatures. However, non-O157 STEC ARG4827
and O157:H7 STEC464 were still detected at 4 C in
glass coverslips, and the latter was only reduced in 1.5
log CFU/mL at 37 C. Reduction on stainless coupons
was more efficient for all strains tested, nevertheless,
EPEC920 and O157:H7 STEC464 were detectable after
24 h [71].
These studies demonstrate the potential of phages
to be used in food products for the biocontrol of E. coli
O157:H7. Phages are a promising tool to control food-
borne pathogens, not only as food additives but also in
the environmental biocontrol throughout the different
steps of the food production chain. Phages can be used
in different ways namely: during the prevention and
control of colonization on livestock, in the reduction of
the number of contaminations on food products, such
as carcasses, or even ready-to-eat products, and lastly,
they can be used to extended shelf life. Despite their
great potential, the use of phage-based products is lim-
ited by some factors such as the type of food matrix
(for instance, some food samples have low water activ-
ity or high salt concentrations, which can impair phage
efficacy) and the food processes (physical and chemical
treatments during food processing can inactivate
phages) [72]. Moreover, the introduction of phages in
the food chain will eventually end up in the ingestion
of phages and in their consequent interaction with the
gut microbiome. This renders phage biocontrol some
concerns, especially due to the fact that dysbiosis phe-
nomena in the gut microbiome have recently been
associated with some diseases [73–75]. In this regard,
some studies have already demonstrated that phages
targeting E. coli in the gut, when administered orally,
can reduce this bacterium without damaging the micro-
biome composition, especially the number of com-
mensal E. coli [76–78]. However, De Sordi et al. [79]
published a study where a host range increase in the
gut was observed in vitro and in vivo. This means that
the phage has gained the ability to infect new hosts,
and sometimes this happens to the detriment of infect-
ing the original host. In the gut, the preferential host
can be in a low number or even absent, which can lead
to greater pressure on the phage [79]. Thus, when
phages are administered to humans, even if in a small
number through the ingestion of food products, a
safety study should be undertaken. The interaction of
phages with the gut microbiome will be addressed in
more detail below.
As can be seen in “Supplementary information,” the
biocontrol of STEC by phages has mainly focused on
the treatment of O157 strains. Nevertheless, lately, with
new developments of detection methodologies, other
serotypes have been recognized as relevant, hence the
prevalence of O157 has been reduced [14].
Nonetheless, E. coli O157 remains the most relevant
pathogenic E. coli. In 2006, the US Food and Drug
Administration (FDA) approved the phage cocktail
EcoshieldTM from Intralytix, Inc (Baltimore, MD) for the
control of this foodborne pathogen in “red meat parts
and trim intended to be ground” [80]. However, the
approval of this product is yet to be achieved in the
European Union.
Phage-based products regulations
As mentioned in the previous section, the phage-based
product EcoShieldTM for control of E. coli O157:H7 was
designed to be used in “red meat parts and the trim is
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intended to be ground” (Retrieved from Intralytix web-
page http://www.intralytix.com/index.php?page=prod&
id=2, August 2019). However, a different product,
Secure Shield E1, from the FINK TEC GmbH company
(Germany) is intended to be used on the “surfaces of
beef carcasses.” Both products have been approved by
the FDA. Recently, PhageGuard E. from Micreos
(Netherlands), a phage mixture from OmniLytics (Sandy,
UT), and EcoShield PXTM from Intralytix obtained
approval to control STEC contamination on several food
products. (Retrieved from GRAS Notices webpage
https://www.fda.gov/food/generally-recognized-safe-
gras/gras-notice-inventory, February 2020). FDA
approved the phage products discussed above as
Generally Recognized as Safe (GRAS) to be used as food
additives. The Federal Food, Drug, and Cosmetic Act
(FD&C Act), as well as the regulations in Title 21 of the
Code of Federal Regulations (21 CFR) are the base for
the aforesaid classification, GRAS. For new substances
intended to be used in human food, such as food addi-
tives, a requirement in accordance with the procedures
in 21 CFR part 170, subpart E, should be submitted to
the FDA [81]. This has been the preferred procedure for
approving phages in the USA. Other countries have
also approved the use of phages for food safety
purposes (Figure 2). In 2014, in the “Guidelines: use of
bacteriophages (bacteria-killing viruses) in food,” the
National Food Service from the Israeli Ministry of
Health, approved all phages that had already been
cleared by the FDA to be used for similar applications
[82]. In Canada, the phage-based products PhageGuard
LTM (formerly ListexTM), ListShieldTM, SalmoFreshTM, and
EcoShieldTM, and others, were approved as a processing
food aid [82,83]. A request for the acceptance of a new
substance should be submitted to the Bureau of
Chemical Safety, within the Health Canada’s Food
Directorate, which will assess the submission and
express an opinion. Health Canada keeps a list of
Antimicrobial Food Processing Aid uses on Red Meat
and Poultry Meat for which “No Objection” was emitted
(Retrieved from https://www.canada.ca/en/health-can-
ada/services/food-nutrition/food-safety/food-additives/
processing-aids.html#a1 in February 2020). In Australia
and New Zealand, the Food Standards Australia New
Zealand approved the use of phage-based preparations
to control Listeria monocytogenes and Salmonella as
Processing Aids for certain RTE products [84].
In Europe, the scenario is quite different. Despite the
fact that the approval of phage-based products has
already been pursued [85,86] and, as of yet, there is no
Figure 2. A worldwide timeline of the phage-based products which have already been approved. Description of products
includes the manufacturing company, the target bacteria and the food matrix where the product is intended to be applied. The
timeline was constructed using information from the FDA, FSANZ, and the companies’ news websites.
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product with the CE marking. As stated in Article 3.2 of
Regulation (EU) 853/2004, which stipulates the hygiene
rules for food of animal origin, “Food business opera-
tors shall not use any substance other than potable
water (… ) to remove surface contamination from prod-
ucts of animal origin, unless use of the substance has
been approved in accordance with the procedure
referred in article 12 (2) (… ).”
The Council, which is the legal entity that approves
the new laws [87] jointly with the European Parliament,
should follow the referred procedure established in
Articles 5 and 6 of Decision 1999/468/EC, the
Regulatory and Safeguard procedures, respectively [88].
For the decision of both procedures, a specialized com-
mittee should deliver its opinion on the subject matter,
in the predetermined time, so a qualified decision can
be made [88]. For phage applications, the Council
requested that the EFSA issues their scientific opinion.
It should be noted that EFSA only provides the scientific
opinion on the products, and is not liable for the final
decision on the approval of such decontamination
products. The European Commission and the Member
States take responsibility for the final approval
(Retrieved from https://www.efsa.europa.eu/en/applica-
tions/biologicalhazard/regulationsandguidance in May
2020). Thus, in 2009, at the request of the European
Commission, the EFSA published a scientific opinion on
“The use and mode of action of bacteriophages in food
production.” The document focuses on the mode of
action of phages when applied on different food surfa-
ces of animal origin, explaining how phages infect bac-
teria, and also how they can be used to control the
growth of pathogens. The EFSA Scientific Committee
could neither conclude if phages were able to control
the recontamination of food with bacterial pathogens,
nor the capability of phages to control the low number
of bacteria naturally present on food products.
Moreover, in the report described, the same scientific
committee provided some recommendations for the
safe use of phages, such as the use of strictly virulent
phages to be used at high MOI. The higher proportion
of phages in relation to the target bacteria is believed
to lead to higher reductions of the latter and diminish
the emergence of BIMs, whose presence should be
avoided if possible. Moreover, the use of phages that
are active against stationary cells (i.e. cells with a lower
metabolic activity) is suggested. For the EFSA scientific
committee, each new phage that seeks approval to be
used as a decontamination substance should submit a
Guidance Document (a case by case analysis), given the
diversity of phage outcomes [89]. Due to their diversity,
phages were excluded from the list of Qualified
Presumption of Safety (QPS) microorganisms to be used
on food and feed by EFSA in 2009. Up to now this
exclusion still applies [90].
Despite the regulatory challenges, the product
ListexTM P100 has sought approval for its use as a
decontamination substance to control Listeria monocy-
togenes on food, raw fish [85], and Ready-to-eat (RTE)
food products [86]. Nevertheless, many food industries
are already using this phage product to control Listeria
in many food products. In October 2019, The European
Court of Justice issued a Court Order that enables food
companies to continue using phages to prevent Listeria
on all ready-to-eat foods in the absence of a legal
EU framework.
Clear and proper legislation for phage-based prod-
ucts does not yet exist on account of the great diversity
of phages [91]. The EFSA considers that any phage-
based product should be seen as unique and a com-
plete study of its efficacy and safety will be required for
approval to be obtained [92]. Accordingly, scientists
and product development companies should direct
their investigation to answer the concerns (reviewed
below) of efficacy and safety that still concerns regula-
tory entities. This would speed up the preparation of
safety and efficacy assessment reports, required in the
regulatory process.
Safety of phage-based products for
STEC biocontrol
The approval of phage-based products to be used as
biocontrol agents in the EU will be dependent on
exhaustive safety analysis. One of the major concerns
raised by the EFSA is the selection of bacteriophage
insensitive mutants (BIM) following a phage application.
In fact, several studies of phage/host interaction show
both a population regrowth shortly after phage applica-
tion, and also part of this population being formed by
BIMs [58,66,93]. Therefore, the selection for BIM is a set-
back for all phages’ applications, including STEC bio-
control. Nonetheless, as overviewed by Moye et al. [94],
the use of a phage cocktail could overcome this prob-
lem. A more complex cocktail (composed of phages tar-
geting different receptors) seems to be a better option
since multiple mutations will be required for the bac-
teria to gain resistance toward all phages within the
cocktail [94]. An advantage of phage biocontrol in rela-
tion to other antimicrobials is the phages’ narrow lytic
spectrum, limiting the number of bacteria cells that will
suffer selection pressure [91].
Another factor to take into account when consider-
ing phage biocontrol for STEC strains is that the major
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virulence factor is the production of Shiga toxins, which
are encoded on the genome of prophages within the
host genome. The expression of this toxin is usually
induced by an external factor that triggers an S.O.S.
response (as revised above). Several factors that may
trigger toxins’ expression have already been studied
elsewhere [26,27,95–98] and they include antibiotics,
among others. It can still be further demonstrated that
phage application is completely safe in this regard, for
example, it is not known if lytic phages could also pro-
mote Shiga toxin release while killing the bacteria. This
needs to be ascertained for any phage which is aimed
to be used in STEC biocontrol. Nevertheless, it is most
likely that phages will not affect Shiga toxin release,
since there is no evidence that their interaction with
the hosts would trigger the S.O.S. response.
Regarding the release of phages into the environ-
ment, STEC strains are commonly found in sewage and
animal wastewaters [99,100]. Therefore, the risk of using
lytic phages should be well assessed. Liao et al. [99]
observed a correlation between the presence of STEC-
specific phages infecting several serogroups, and lower
isolation of STEC strains in pre-harvest produce environ-
ments. It is worth mentioning that in this study the
phages were isolated, especially in areas of human
impact [99]. The phages found seem to be able to con-
trol the levels of bacteria load, and hence are an
important component of the ecosystem. In the context
of biocontrol and safety using a phage cocktail toward
STEC, it is important to assess the real impact of such
an application on the environment where phages will
inevitably be discharged. The use of phages for the bio-
control of STEC is of great interest since the E. coli spe-
cies is a very heterogeneous group, classified in
different serogroups which are characterized by having
different O-antigens [101]. An effort should be made to
select phages that recognize strains of specific virulent
serogroups, ensuring limited lytic activity toward other
E. coli considered commensal in a certain ecosystem.
Additionally, several studies noted that some dietary
alterations, antibiotics or even the ingestion of phages
can alter the gut microbiota [102–106]. As E. coli is an
important commensal of human microbiota [1], any
possible disturbance can lead to severe outcomes (See
Figure 3). When a phage-based product that has the
potential risk of disturbing the normal E. coli population
it is intended to be used in food (and, thus, is ingested),
this risk should be further analyzed.
Figure 3. Possible interaction of phages with the gut microbiome. In the healthy gut microbiome, bacteria and phages are natur-
ally present (A); when an exogenous phage is administered to control an infection, it will target the susceptible host, whether
they are the intended target-host (B) or a different host on the gut microbiome, leading to a dysbiosis (C). Exogenous phage can
adapt to infect commensal bacteria (D).
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How is the GUT microbiome affected
by phages?
Some studies report on the use of phages to control
food contamination by targeting the pathogen on liv-
ing animals prior to their slaughter or by applying them
as disinfectants on food processing steps (revised else-
where [107–109]). The inclusion of phages on the food
chain will result in their presence on the consumers’
table and their gut. While the direct impact of phages
on human health has been superseded by some of the
products being commercialized (and also by the long
tradition of phage-based therapeutics in Western
Europe) that have proved them as safe, the impact on
the gut microbiome can be significant. This is even
more relevant for E. coli that has been regarded as one
of the most important species in the commensal gut
[1]. In 2004, Bruttin et al. have already demonstrated
that phage T4 (specific for E. coli) could survive the GI
tract which appears on the feces of human volunteers.
However, at that time the composition of the gut
microbiome was not evaluated. The phage used has a
very narrow lytic spectrum, and it is very likely that no
encounter with a suitable host will occur during the gut
passage. This was in fact verified since no replication of
the phage was observed [110].
Nowadays, there is a consensus regarding the fact
that the gut microbiome (comprising bacteria, fungi,
archaea, viruses, and protozoans) is of the utmost
importance for human health. The dysbiosis of the gut
microbiome can lead to severe diseases, and dietary,
antibiotics, and other stress factors can be responsible
for it [111]. In the gut microbiome, the most predomin-
ant viruses are phages. Recently, several metagenomics
undertaken studies have elucidated the presence of
phages, the temperate phages being the most common
ones. Nevertheless, only a few studies have tried to
answer the important questions: how do phages influ-
ence the microbiome, and what is the relationship
between bacteria, phages, and the subjects’ health con-
ditions? [79] Two trials aiming to assess the safety of
the phage in children were performed in Bangladesh
by Sarker et al. in 2016 and 2017. Clinical trials were
performed either in diarrheal children, or in both
healthy and diarrheal children, demonstrating that the
use of phage cocktails (containing T4 or T7-like viruses)
are safe, and do not alter the composition of the gut
microbiome [76,112]. It should be noted that the gut
microbiome variability of the population in the study
was independent of phage treatment [76,112]. In any
case, in these studies, the cocktail used was not cus-
tomized for the pathogens that lead to diarrhea, which
can mean that most probably there was a lack of
replication of phages in the gut. The phage amount
recovered in the feces was never superior to the one
given orally. Another possible explanation for the incap-
acity of phages to replicate in the gut consists of the
low amounts of the pathogen which is responsible for
diarrhea. The fact that phages did not replicate also
explains the lack of improvement of diarrheal symp-
toms [112]. Nonetheless, the fact is that this study
mimics quite well what happens with phages applied in
food samples. Phages are subsequently ingested by
healthy humans who - at least in theory – do not have
the target pathogen in their gut.
Recently, Gindin et al. [113] accomplished an evalu-
ation of the safety and tolerability of probiotic-contain-
ing phages, such as PreforPro (composed of 4 lytic
phages targeting E. coli – K12, 16 enterotoxigenic
strains and 2 enterohemorrhagic strains). In the above-
mentioned study, each participant received random
phage treatment or a placebo for 28 days, followed by
a washout period (14 days) before starting the opposite
treatment for an additional 28 days. The authors con-
cluded that the use of the probiotic formulation was
safe and tolerated for human consumption, and also
that it can be used by a healthy individual that shows
mild to moderate symptoms of gastrointestinal distress
[113]. Nevertheless, in this study, the composition of
the gut microbiome was not assessed and conse-
quently, it is not possible to affirm that the PreforPro is
completely safe and able to control the symptoms
of diarrhea.
The number of clinical trials that focus on studying
the effect of phages on the gut environment is still
quite scarce [112], and most studies are performed in
simulated gut conditions or in animal models
[78,79,114]. The observations made by Maura et al.
[115] suggest that, as was to be expected, phages are
able to replicate only when in the presence of the host
in the mice gut. The authors used 3 specific phages for
the strain O104:H4 EAEC 55989Str and observed that
after only one application administered by oral gavage
could replicate for a period of 2weeks; however, the
colonization levels of bacterium 55989Str on the mice
feces would not be compromised. When, in the
absence of a suitable host, the phages were not
detected after day 9 of the application [115]. A similar
study was undertaken by Cieplak et al. [78]: phage
cocktail Ec17B153DK1, composed of 3 phages (ECML-
363, ECML-122, and ECML-359), with lytic activity
against E. coli DSM 1058, was tested in a small intestine
simulated model. A consortium of microorganisms
comprising 7 bacterial species was used to simulate a
normal and healthy microbiome. The phage cocktail,
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unlike the antibiotic ciprofloxacin, was able to reduce
the target bacterium without compromising the com-
mensal bacteria. It should be noted that, in the simu-
lated model of the small intestine, only the target E. coli
was used together with the other 7 species, however,
phages were able to lyse other E. coli strains when
tested in vitro. This suggests that phages used in this
study could potentially lyse further E. coli strains in the
gut [78]. In fact, the ability of phages to adapt to new
hosts was demonstrated by De Sordi et al. [79], sug-
gesting that bacterial diversity encountered by phages
in the intestinal microbiota promotes genome diversifi-
cation of phages [79] (Figure 3). So, despite the high
specificity of phages, it is very likely that they might
cause alteration in the gut microbiome by targeting
commensal E. coli strains that display compatible recep-
tors or, even as demonstrated by De Sordi et al. [79], by
phages adaptation to new susceptible hosts. It is not
yet clear if a potential interference with the gut micro-
biome could cause an imbalance, questioning the
safety of phage application. These concerns need to be
addressed by further, more in-depth microbiome stud-
ies, before phage therapy, can be adopted as a routine
tool in the control of foodborne pathogens. In that
sense, considering the relevance/prevalence of E. coli in
the gut and its close phylogenetic relationship with sev-
eral foodborne pathogens, this bacterium constitutes
the ideal case study for future works in that field.
Concluding remarks
In an era of constant innovation and a search for new
and more natural forms to control pathogens in food
[94], phages have now acquired a renewed interest.
The approval of phage-based products for the control
of STEC strains is a reality in some countries, such as
the USA, with some phage cocktail being considered
GRAS by the FDA [116]. Still, in the European Union,
there is concern regarding the use of these products
due to the lack of safety and long-term studies on the
effects of the release of phages into the environment.
Nevertheless, these concerns might be addressed when
proper guidelines and legislation are established for
phage or phage-derived products. This will also
increase the companies’ willingness for investing in
such products. Hitherto, studies have proved E. coli spe-
cific phages to be efficient tools for the biocontrol of
STEC in food products, and some have even shown to
be safe in humans. Nonetheless, recent developments
on how human/animal microbiomes affect health con-
ditions, adds an extra layer of complexity to phage
application. The introduction of foreign phages for the
control of an important inhabitant of the gut environ-
ment should be thoroughly analyzed to ascertain the
possible outcomes on human health. When both this
legislation and safety concerns are set aside we might
face a new era of antimicrobials with an application at
different value chains, starting with farm-level interven-
tions, up to food decontamination, and human
treatment.
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